meta
|
evidence
oncology
Living systematic review and meta-analysis
endometrial cancer - (neo)adjuvant (NA)
1
esophageal cancer (EC)
immune chekpoint inhibitors
anti-PD-(L)1
camrelizumab based treatment
camrelizumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC